MARKET OUTLOOK

Dyslipidemia is an important modifiable risk factor for CV disease and is primarily managed with statin therapy. Based on the positive CVOT data for certain nonstatin therapies, including the PCSK9 inhibitors and Vascepa, physicians are eagerly seeking the ability to reduce the mortality rate and the risk of CV morbidity in their dyslipidemia patients. We discuss how current therapies are differentiated based on the performance of key drug attributes and measure the impact of these attributes on physicians’ prescribing behavior. We also assess the most important unmet needs in the treatment of dyslipidemia and consider which emerging therapies, if any, can capitalize on these opportunities. Our conjoint analysis reveals the key trade-offs that surveyed physicians are willing to make for these attributes when considering new treatment options for dyslipidemia.

QUESTIONS ANSWERED

  • Which drug attributes are key influencers, which have a limited impact, and which are hidden opportunities?
  • Which dyslipidemia therapies are perceived by U.S. and European physicians as performing best on key treatment drivers and goals?
  • What are the major areas of opportunity for drug developers in dyslipidemia treatment and their likelihood of being fulfilled in the near future?
  • Based on the conjoint analysis and TPP simulation, what trade-offs across different clinical attributes and price are acceptable to U.S. and European physicians for a hypothetical new dyslipidemia drug?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 34 European cardiologists and endocrinologists fielded in January 2019

Key companies: Amarin Corporation, Amgen, and Sanofi/Regeneron Pharmaceuticals

Key drugs: Ezetimibe, statins, fibrates, Praluent, Repatha, Vascepa, and omega-3-acid ethyl ester (Lovaza)

Table of contents

  • Dyslipidemia - Unmet Need - Detailed, Expanded Analysis
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Convenience of Administration
      • Rationale for Drug Selection
        • Products for Dyslipidemia
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Cardiologists' and Endocrinologists' Prescribing Decisions in Dyslipidemia
      • Importance of Efficacy Attributes to Prescribing Decisions in Dyslipidemia: United States
      • Importance of Efficacy Attributes to Prescribing Decisions in Dyslipidemia: Europe
      • Importance of Convenience of Administration Attributes to Prescribing Decisions in Dyslipidemia: United States
      • Importance of Convenience of Administration Attributes to Prescribing Decisions in Dyslipidemia: Europe
      • Key Findings: Stated vs. Derived Importance
      • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Dyslipidemia: United States
      • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Dyslipidemia: Europe
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
      • Overall Performance of Key Therapies for Dyslipidemia: United States
      • Overall Performance of Key Therapies for Dyslipidemia: Europe
      • Mean Overall Performance of Key Therapies for Dyslipidemia: United States and Europe
      • Relative Performance of Key Therapies for Dyslipidemia Across Select Efficacy Attributes: United States
      • Relative Performance of Key Therapies for Dyslipidemia Across Select Efficacy Attributes: Europe
      • Relative Performance of Key Therapies for Dyslipidemia Across Select Convenience of Administration Attributes: United States
      • Relative Performance of Key Therapies for Dyslipidemia Across Select Convenience of Administration Attributes: Europe
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Dyslipidemia
      • Surveyed Cardiologists’ and Endocrinologists' Satisfaction with the Performance of Key Therapies for Dyslipidemia on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
      • Surveyed Cardiologists’ and Endocrinologists' Satisfaction with the Performance of Key Therapies for Dyslipidemia on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
      • Surveyed Cardiologists' and Endocrinologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Dyslipidemia: United States
      • Surveyed Cardiologists' and Endocrinologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Dyslipidemia: Europe
      • Surveyed Cardiologists' and Endocrinologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Dyslipidemia: United States
      • Surveyed Cardiologists' and Endocrinologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Dyslipidemia: Europe
      • Key Findings: Unmet Need in Dyslipidemia and Related Indications
      • Surveyed Cardiologists' and Endocrinologists' Ascribed Level of Unmet Need in Dyslipidemia and Related Indications: United States
      • Surveyed Cardiologists' and Endocrinologists' Ascribed Level of Unmet Need in Dyslipidemia and Related Indications: Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Dyslipidemia Market and Emerging Therapy Insights
        • Opportunity: A Nonstatin Agent Offering a Proven Reduction in Cardiovascular Morbidity and All-Cause Mortality
        • Opportunity: A Novel Non-LDL-C-Lowering Therapy with a Positive Cardiovascular Benefit
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • Dyslipidemia Target Product Profile: Attribute Importance
        • Reduction in rate of cardiovascular morbidity (in addition to standard of care)
        • Reduction in mortality rate (in addition to standard of care)
        • Effect on LDL-C levels (from baseline)
        • Effect on lipoprotein(a) [Lp(a)] (from baseline)
        • Effect on TG levels (from baseline)
        • Dosing burden (route of administration and frequency)
        • Price per day
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Dyslipidemia Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • Dyslipidemia Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • Dyslipidemia Market Simulations: Target Product Profiles Included in Scenario 1
        • Dyslipidemia Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • Dyslipidemia Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • Dyslipidemia Market Simulations: Target Product Profiles Included in Scenario 2
    • Appendix
      • Key Abbreviations
      • Bibliography

Author(s): Pallavi Malik, M.Sc.

Pallavi Malik is a business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group.

She obtained an M.Sc. degree with specializations in Biotechnology, and a Bachelor's degree in Science from the Panjab University, Chandigarh, India. Prior to joining DRG, she has worked as a Senior Business Analyst at the research firm Evalueserve. Her role involved in-depth scientific secondary research, and competitive intelligence across multiple domains (such as oncology, ophthalmology and CVD) including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, competitor benchmarking, and opportunity assessment.

 


Related Reports

Dyslipidemia - Landscape & Forecast - Disease Landscape & Forecast

Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current...

View Details

Dyslipidemia | Disease Landscape and Forecast | G7 | 2020

Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current lipid-modifying therapies include statins, ezetimibe, fibrates, omega-3 fatty acid compounds...

View Details

Dyslipidemia - Epidemiology - Mature Markets

DRG Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dyslipidemia for each co...

View Details